focus -WSS

focus

author：Wikipedia 2025-10-01 23:05:43 - browse：31181

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

The benefits and risks of Eli Lilly’s treatment for Alzheimer’s disease were confirmed in detailed scientific disclosures Monday, paving the way for its full approval but leaving physicians with lingering questions about the medicine’s impact on patients as a new era in Alzheimer’s therapy unfolds.

The drug, called donanemab, showed a 35% slowing of Alzheimer’s disease progression relative to placebo in a clinical trial that enrolled 1,700 patients with early-stage disease. Numerically, that’s a modest, 3.3-point improvement on a 144-point survey, called the Integrated Alzheimer’s Disease Rating Scale, or iADRS, that combines measures of cognition and function, such as driving, managing finances, or carrying on conversations.

There was a similar benefit when donanemab’s efficacy was assessed using a more common measure of cognition called the Clinical Dementia Rating-Sum of Boxes, or CDR-SB. On that scale, the Lilly drug showed a 36% slowing of cognitive decline relative to placebo, or 0.68 points on an 18-point scale.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： How one medical school became remarkably diverse
Next article： Health tech startups drop sharply from 2021 highs

knowledge

hotspot

WSS

Novo: Oral version of Ozempic leads to 15% weight loss

FDA seeks to regulate lab

Bispecific antibodies are next new thing in cancer immunotherapy

Covid vaccines: Private market messier than government rollout

Menendez indictment could see pharma lose a key ally

Tennessee law changes starting July 1 will restrict trans health care and fund more school safety

explore

focus

Wikipedia

Cancer drug shortages should be causing more outrage

Data show record exodus of life scientists from academia

Jerome Adams on the need for new antivirals for Covid

Mom launches Girl Scout troop for LGBTQ youth in Texas

Apple is now the first public company to be valued at $3 trillion

Why do women spend more than men on medical expenses?

Novavax promises a turnaround & Lilly roils the obesity market

Would Medicare drug price negotiations stall in a shutdown?

Peter Hotez and the public health issue of online harassment

Bispecific antibodies are next new thing in cancer immunotherapy

entertainment

Xenotransplantation trials will require adjusting expectations, experts say

Eli Lilly’s Mounjaro succeeds in second weight

Researchers use wearables data and AI to predict preterm birth risk

Timeline: Key moments in fight for gay rights

Senator probes 340B programs at Cleveland Clinic, Bon Secours

We're not in Australia anymore: Kansas cops jump into action to save kangaroo

knowledge

hotspot

leisure time

hotspot